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Abstract
Background: Chronic obstructive pulmonary disease (COPD) patients often have dysphagia through age and
several co-morbidities, leading to aspiration pneumonia (AsP). COPD patients also have increased risk of developing
community-acquired pneumonia (CAP). Using a national inpatient database in Japan, we aimed to compare clinical
characteristics and outcomes between AsP and CAP in COPD patients and to verify the factors that affect in-hospital
morality.
Methods: We retrospectively collected data on COPD patients (age ≥40 years) who were admitted for AsP or CAP in
1,165 hospitals across Japan between July 2010 and May 2013. We performed multivariable logistic regression analyses
to examine the association of various factors with all-cause in-hospital mortality for AsP and CAP.
Results: Of 87,330 eligible patients, AsP patients were more likely to be older, male and have poorer general condition
and more severe pneumonia than those with CAP. In-hospital mortality in the AsP group was 22.7 % and 12.2 % in the
CAP group. After adjustment for patient background, AsP patients had significantly higher mortality than CAP patients
(adjusted odds ratio, 1.19; 95 % confidence interval, 1.08–1.32). Subgroup analyses showed higher mortality to be
associated with male gender, underweight, dyspnea, physical disability, pneumonia severity, and several co-morbidities.
Further, older age and worse level of consciousness were associated with higher mortality in the CAP group, whereas
those were not associated in the AsP group.
Conclusions: Clinical characteristics differed significantly between AsP and CAP in COPD patients. AsP patients had
significantly higher mortality than those with CAP.
Keywords: Aspiration pneumonia, Chronic obstructive pulmonary disease, Community-acquired pneumonia,
Mechanical ventilation, Mortality
Background
Chronic obstructive pulmonary disease (COPD) is the
third leading cause of death in the world [1]. COPD is
characterized by persistent airflow limitation associated
with chronic airway inflammation [2]. Often, exacerbation
of COPD occurs in the clinical course of the disease,
accelerates the rate of decline in lung function [3], and
is associated with significant mortality, particularly in
patients requiring hospitalization [4]. The most com-
mon cause of exacerbation appears to be respiratory
tract infection; it has been reported that exacerbation is
caused by bacterial infection in approximately 50 % of
cases [5]. Further, COPD is one of the most frequent
co-morbid conditions associated with the development
of community-acquired pneumonia (CAP) [6]; COPD is
the most common underlying disease in patients with
CAP who require hospitalization [7], and such patients
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have increased mortality [8, 9]. Thus, CAP should be
considered as a cause of exacerbation in the differential
diagnosis and treated appropriately if present [2].
Aspiration pneumonia (AsP) is assumed to be one of
the phenotypes of CAP. AsP demonstrates specific clinical
features [10, 11], such as frequent occurrence in elderly pa-
tients, greater severity of pneumonia, and poorer long-term
mortality compared with CAP [11–13]. COPD patients
have been reported to have increased risk of dysphagia,
which is related to the occurrence of AsP. This dysphagia is
due to ageing [13] and also to the presence of cerebrovas-
cular disease [11] and gastro-oesophageal reflux disease
[14] as co-morbidities of COPD. COPD patients have
reduced laryngopharyngeal sensitivity and impaired swal-
lowing function compared with healthy age-matched
controls [15, 16]. AsP should therefore be considered
in the differential diagnosis in COPD patients with ex-
acerbation who require hospitalization.
However, there is little information about the clinical
features of COPD patients with AsP compared with those
with CAP—particularly with respect to in-hospital mortal-
ity. Therefore, the purpose of this study was to compare
clinical characteristics and outcomes between AsP and
CAP in COPD patients using a national inpatient data-
base in Japan. We also aimed to evaluate factors that




This study used the Diagnosis Procedure Combination
database, a nationwide inpatient database in Japan. The
database includes administrative claims data and dis-
charge abstract data. With this database, the primary
diagnosis on admission, co-morbidities present, and com-
plications during hospitalization are recorded using the
International Classification of Disease and Related Health
Problems, 10th Revision (ICD-10) codes accompanied by
text data in Japanese. The database also contains the
following details: patient’s age, sex, body height, and
weight; severity of dyspnea based on the Hugh-Jones
dyspnea scale (details of dyspnea scale appear in Additional
file 1: Additional Information); level of consciousness based
on the Japan Coma Scale [17, 18] on admission (details
of the Japan Coma Scale are shown in Additional file 1:
Additional Information); grades of activities of daily life
on admission converted to the Barthel index [19] (de-
tails of the Barthel index appear in Additional file 1:
Additional Information); severity of pneumonia based
on the A-DROP score (details of the A-DROP scoring
system are shown in Additional file 1: Additional Infor-
mation); admission to intensive care unit (ICU) during
hospitalization; mechanical ventilation; outcome; and dis-
charge status. Body mass index (BMI) was defined as body
weight (kg) divided by the square of body height (m2; de-
tails of BMI categorization appear in Additional file 1:
Additional Information).
This study was approved by the Institutional Review
Board of The University of Tokyo. The board waived the
requirement for patient informed consent because of the
anonymous nature of the data.
Patient selection
We retrospectively collected data for patients aged over
40 years who had been admitted to hospital because of
AsP (ICD-10 code J69) or pneumonia caused by mi-
crobes (J10–J18) as the main diagnosis on admission,
who had a diagnosis of COPD (J41–J44), and who
were discharged between 1 July 2010 and 31 March
2013. To preclude hospital-acquired and ventilator-
associated pneumonia, we excluded patients who had
pneumonia recorded as a post-admission complication.
The presence of COPD was based on physician diagnosis.
We divided the patients into those with AsP and CAP.
Co-morbidities on admission
We identified co-morbidities on admission using ICD-10
codes (detailed ICD-10 codes appear in Additional file 1:
Additional Information): interstitial pneumonia; lung
cancer; heart failure; ischemic heart disease; cardiac
arrhythmia; pulmonary embolism; cor pulmonale; cere-
brovascular disease; chronic liver disease; chronic renal
failure; anxiety; depression; and bone fracture.
A-DROP score
We evaluated the severity of pneumonia using the A-
DROP score, which is a scoring system for the clinical
severity of community-acquired pneumonia adopted by
the Japanese Respiratory Society; it is similar to the
CURB-65 of the British Thoracic Society [20]. We cat-
egorized the severity of pneumonia into four classes
using the A-DROP score: mild, 0; moderate, 1–2; severe,
3; and extremely severe, 4–5.
Clinical outcomes
The outcomes of this study were all-cause in-hospital
mortality, length of hospital stay (days), length of ICU
stay (days), requirement of mechanical ventilation, dur-
ation of mechanical ventilation (days), and mortality of
patients who underwent mechanical ventilation.
Statistical analysis
We used the chi-square test to compare proportions, the
two-sample t test to compare average values, and the
Mann–Whitney test to compare the median values be-
tween the groups. We performed multivariable logistic
regression analyses to assess the relationship between
patient-level factors and mortality in the following COPD
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patients—after adjustment for within-hospital clustering
by means of a generalized estimating equation [21]: (1) all
patients with pneumonia, including both AsP and CAP;
(2) patients with AsP alone; and (3) those with CAP alone.
The threshold for significance was a value of p < 0.05. We
performed all statistical analyses using SPSS Statistics for
Windows, Version 22.0 (IBM Corp., Armonk, NY, USA).
Results
Comparison of clinical characteristics between AsP and
CAP in patients with COPD
We identified 87,330 patients with COPD (age ≥40 years)
who were admitted for pneumonia; 16,388 had AsP, and
70,942 had CAP. The patient characteristics appear in
Table 1. The average age in the AsP group was 82.7 years,
which was significantly older than that in the CAP group
(77.4 years). The average BMI in the AsP group was
18.5 kg/m2, which was significantly lower than that in
the CAP group (19.9 kg/m2). The proportion of patients
with severe dyspnea grade, low level of consciousness,
and low Barthel index on admission was higher in the
AsP group than in the CAP group; thus, the general
condition on admission was poorer in the AsP group
than in the CAP group. Regarding severity of pneumo-
nia, the median A-DROP score in the AsP group was 2
(interquartile range; IQR, 2–3), which was higher than
that in the CAP group (2, IQR, 1–3); the proportion of
severe pneumonia was higher in the AsP group than in
the CAP group. Co-morbidities on admission are pre-
sented in Table 2. The proportion of cerebrovascular
disease in the AsP group was approximately 3-fold that
in the CAP group. The proportion of bone fractures in
the AsP group was 2-fold that in the CAP group.
Comparison of outcomes between AsP and CAP in
patients with COPD
The outcomes appear in Table 3. All-cause in-hospital
mortality in the AsP group was 22.7 %, whereas it was
12.2 % in the CAP group. Hospital stay in the AsP group
was longer than in the CAP group. The proportions of
ICU admission and requirement of mechanical ventilation
in the AsP group were higher than in the CAP group. The
length of ICU stay was similar in the two groups. The
mortality rate in patients who required mechanical venti-
lation in the AsP group was 51.8 % (n = 1,010/1,951),
which was significantly higher than in the CAP group
(41.4 %, n = 3,036/7,339).
Multivariable logistic regression analysis for all-cause
in-hospital mortality
The results of the multivariable logistic regression analysis
for all-cause in-hospital mortality are presented in Table 4.
In the analysis for all patients (left-hand column, Table 4),
AsP was significantly associated with higher mortality
(adjusted odds ratio, 1.19; 95 % confidence interval,
1.08–1.31; p = 0.001) than CAP. Higher mortality was
associated with older age, male gender, lower BMI, more
severe dyspnea scale, worse level of consciousness, worse
level of activities of daily life, and more severe pneumonia.
Higher mortality was also associated with several co-
Table 1 Patient backgrounds on admission
AsP (n = 16,388) CAP (n = 70,942) p
Age (years) † 82.7 ± 8.0 77.4 ± 9.5 <0.001
40–64 426 (2.6) 7,318 (10.3)
65–74 1,851 (11.3) 16,562 (23.3)
75–84 6,935 (42.3) 30,759 (43.4)
≥85 7,176 (43.8) 16,303 (23.0)
Sex <0.001
Male 13,328 (81.3) 58,815 (82.9)
Female 3060 (18.7) 12,127 (17.1)
Body mass index (kg/m2)† 18.5 ± 3.6 19.9 ± 3.8 <0.001
<18.5 7,196 (54.9) 23,835 (39.0)
18.5–24.9 5,338 (40.7) 31,964 (52.3)
25.0–29.9 512 (3.9) 4,684 (7.7)
>30 58 (0.4) 631 (1.0)
Dyspnea scale <0.001
I 562 (3.8) 6159 (9.4)
II 966 (6.5) 8,991 (13.7)
III 1,239 (8.4) 9,001 (13.7)
IV 2,509 (16.9) 16,277 (24.8)
V 4,284 (28.9) 16,885 (25.7)
Unspecified 5,273 (35.5) 8,348 (12.7)
Level of consciousness <0.001
Alert 10,233 (62.5) 60,993 (86.0)
Dull 4,048 (24.7) 7,220 (10.2)
Somnolence 1,379 (8.4) 1,610 (2.3)
Coma 724 (4.4) 1,116 (1.6)
ADL level <0.001
20 1,633 (11.2) 23,281 (37.8)
15–19 1,124 (7.7) 8,462 (13.7)
10–14 1,614 (11.1) 9,887 (16.0)
5–9 1,590 (10.9) 6,113 (9.9)
0–4 8,598 (59.1) 13,927 (22.6)
A-DROP score ‡ 2 [2, 3] 2 [1–3] <0.001
Mild 175 (1.9) 4,293 (8.8)
Moderate 4,833 (53.7) 31,067 (63.6)
Severe 2,352 (26.1) 9,630 (19.7)
Extremely severe 1,641 (18.2) 3,868 (7.9)
Data are expressed as numbers (%), unless otherwise indicated; † data are
expressed as averages ± standard deviation; ‡ data are expressed as medians
[interquartile range]. Abbreviations: AsP aspiration pneumonia, CAP community-
acquired pneumonia, ADL activities of daily life
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morbidities on admission, including interstitial pneumonia,
lung cancer, heart failure, cor pulmonale, chronic renal fail-
ure, and bone fracture.
Subgroup analyses of the AsP and CAP groups (center
and right-hand columns, Table 4) showed that higher
mortality was commonly associated in both groups with
male gender, underweight, dyspnea, physical disability,
severe pneumonia, interstitial pneumonitis, lung cancer,
heart failure, and chronic renal failure. Further, older age
and worse level of consciousness were associated with
higher mortality in the CAP group, whereas those were
not associated with mortality in the AsP group.
Discussion
Using a national inpatient database in Japan, we compared
clinical characteristics and outcomes between AsP and
CAP in patients with COPD. The AsP group was more
likely to be older, male, have lower BMI, more severe dys-
pnea, worse levels of consciousness, worse activities of
daily life level, and greater severity of pneumonia than the
CAP group. Mortality in the AsP group was significantly
higher than in the CAP group—even after adjustment for
patient backgrounds.
It is well known that there is a high incidence of as-
piration in the elderly, and it is an important risk factor
in CAP [22]. One study has reported the incidence of
aspiration in elderly CAP patients to be 71 %, which was
significantly higher than control subjects without acute
disease (10 %) [23]. In addition, COPD patients have been
found to have a high incidence of impairment of the
swallowing reflex, which is a risk factor for exacerbation
of COPD [14, 24] and is related to the presence of gastro-
oesophageal reflux disease as a co-morbidity [14, 25]. Fur-
ther, COPD patients have increased risk of mild cognitive
impairment [26], which is associated with swallowing diffi-
culties [27]. Moreover, patients with COPD have impaired
laryngopharyngeal sensitivity, which leads to inability
to detect pharyngeal residue and subsequent aspiration
of pharyngeal contents [15]. Thus, COPD patients have
increased risk of AsP.
AsP is believed to be one of the phenotypes of CAP.
Although there are no definitive diagnostic criteria of
AsP, it is generally characterized by aspiration of oropha-
ryngeal contents into the larynx and lower respiratory
tract [10, 28]. Previous studies have demonstrated that
AsP has distinct clinical characteristics: compared with
CAP, it appears at an older age in individuals with lower
BMI and is associated with greater severity of pneumonia
and increased long-term mortality [11, 12]. The present
study found the clinical characteristics on admission in
the AsP group to be similar to those reported in previous
investigations [11, 12], and AsP in COPD patients also has
distinct clinical features.
Regarding mortality, it is controversial whether or not
the presence of AsP in the general population is an inde-
pendent short-term prognostic factor. After adjusting for
co-morbidities and severity of pneumonia, some studies
[11, 12] have found that AsP was not associated with
short-term mortality. Adopting a strict diagnosis for AsP,
another investigation [29] has demonstrated that AsP is an
independent prognostic factor for short-term mortality in
pneumonia patients. Our search of the medical literature
Table 2 Co-morbidities on admission
AsP CAP p
n = 16,388 (%) n = 70,942 (%)
Interstitial pneumonia 357 (2.2) 3,619 (5.1) <0.001
Lung cancer 728 (4.4) 6,983 (9.8) <0.001
Heart failure 3,350 (20.4) 12,704 (17.9) <0.001
Ischemic heart disease 998 (6.1) 4,619 (6.5) 0.048
Cardiac arrhythmia 880 (5.4) 3,560 (5.0) 0.065
Pulmonary embolism 31 (0.2) 206 (0.3) 0.025
Cor pulmonale 110 (0.7) 806 (1.1) <0.001
Cerebrovascular disease 2,816 (17.2) 3,992 (5.6) <0.001
Chronic liver disease 171 (1.0) 1,102 (1.6) <0.001
Chronic renal failure 345 (2.1) 1,525 (2.1) 0.723
Anxiety/depression 227 (1.4) 1,025 (1.4) 0.562
Bone fracture 353 (2.2) 812 (1.1) <0.001
Data are expressed as numbers (%) in each category. Abbreviations: AsP
aspiration pneumonia, CAP community-acquired pneumonia
Table 3 Clinical outcomes
AsP (n = 16,388) CAP (n = 70,942) p
Death 3,726 (22.7) 8,671 (12.2) <0.001
Length of stay (days) 21.0 [12–40] 15.0 [10–26] <0.001
ICU admission 522 (3.2) 2021 (2.8) 0.021
Length of ICU stay (days) 4.0 [2–10] 4.0 [2–9] 0.527
Mechanical ventilation 1,951 (11.9) 7,339 (10.3) <0.001
Duration of mechanical ventilation (days) 6.0 [1–21] 7.0 [2–20] 0.001
Death† 1,010 (51.8) 3,036 (41.4) <0.001
Data are expressed as numbers (%) or medians [interquartile range];†% indicates the proportion of patients who died, among those who underwent mechanical
ventilation. Abbreviations: AsP aspiration pneumonia, CAP community-acquired pneumonia, ICU intensive care unit
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Table 4 Multivariable logistic regression analysis for in-hospital death
All AsP CAP





40–64 Ref. Ref. Ref.
65–74 1.13 0.93–1.38 1.43 0.75–2.71 1.09 0.87–1.35
75–84 1.28* 1.05–1.56 1.52 0.80–2.91 1.22 0.98–1.52
>85 1.45** 1.18–1.77 1.58 0.83–2.97 1.41** 1.12–1.77
Sex
Male Ref. Ref. Ref.
Female 0.60** 0.54–0.67 0.66** 0.52–0.83 0.58** 0.52–0.66
Body mass index (kg/m2)
<18.5 1.70** 1.58–1.83 1.72** 1.50–1.96 1.69** 1.55–1.84
18.5–24.9 Ref. Ref. Ref.
25–29.9 0.77** 0.65–0.93 0.73 0.48–1.12 0.77* 0.63–0.95
>30 0.88 0.56–1.38 0.79 0.24–2.55 0.90 0.52–1.47
Dyspnea grade by Hugh-Jones classification
I Ref. Ref. Ref.
II 1.23 0.89–1.68 0.64 0.33–1.22 1.42 1.00–2.02
III 1.51** 1.13–2.01 0.90 0.51–1.58 1.68** 1.21–2.34
IV 2.26** 1.74–2.96 1.30 0.76–2.22 2.57** 1.89–3.50
V 5.44** 4.19–7.08 2.60** 1.55–4.37 6.42** 4.72–8.72
Unspecified 5.54** 4.20–7.29 2.47** 1.46–4.19 6.90** 4.99–9.53
Level of consciousness
Alert Ref. Ref. Ref.
Dull 0.96 0.86–1.07 0.88 0.75–1.03 1.00 0.88–1.14
Somnolence 1.09 0.94–1.27 0.82 0.64–1.04 1.38** 1.12–1.70
Coma 1.46** 1.19–1.80 1.22 0.88–1.68 1.62** 1.24–2.10
Level of ADL scored by Barthel index
20 Ref. Ref. Ref.
15–19 1.26** 1.09–1.45 1.07 0.73–1.59 1.26** 1.07–1.48
10–14 1.54** 1.34–1.76 1.33 0.93–1.90 1.51** 1.31–1.75
5–9 1.90** 1.65–2.20 1.22 0.85–1.75 1.99** 1.69–2.35
0–4 3.04** 2.67–3.46 1.94** 1.43–2.63 3.21** 2.76–3.71
A-DROP score
Mild Ref. Ref. Ref.
Moderate 1.64** 1.24–2.17 3.22* 1.15–9.00 1.48* 1.09–2.01
Severe 2.86** 2.12–3.85 5.11** 1.78–14.65 2.67** 1.94–3.68
Extremely severe 7.84** 5.74–10.70 14.18** 4.85–41.41 7.22** 5.15–10.12
Co-morbidities on admission
IP 2.21** 1.88–2.60 1.69* 1.12–2.55 2.32** 1.95–2.76
Lung cancer 2.80** 2.45–3.20 1.88** 1.40–2.52 3.00** 2.59–3.48
Heart failure 1.16** 1.06–1.27 1.27** 1.06–1.53 1.14* 1.00–1.24
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revealed no report that focused on AsP mortality in COPD
patients. The present study showed AsP in COPD patients
to be associated with higher short-term mortality—even
after adjustment for patient backgrounds. The association
between AsP in COPD and mortality could be attributed
to the following: AsP patients easily develop recurrent
pneumonia [11], which causes a deterioration in lung
function in COPD patients [3]; because COPD patients
have increased risk of aspiration, COPD patients with
AsP have more repetitive aspiration events—even during
hospitalization [29]. Thus, AsP in COPD patients would
appear to be associated with higher mortality.
The length of hospital stay in the AsP group was sig-
nificantly greater than in the CAP group, which is con-
sistent with the results of previous studies that focused
on AsP. [11, 12, 30] Likewise, the proportions of ICU
admission and requirement of mechanical ventilation
were higher in the AsP than in the CAP group, which
is a similar finding to that reported elsewhere [11, 30].
To our knowledge, no previous study has examined
AsP mortality in COPD patients who require mechanical
ventilation. One investigation on mortality in CAP pa-
tients undergoing mechanical ventilation found an overall
mortality rate of 32 % [31]; the mortality in the AsP group
in the present study was 51.8 %, which is much higher
than the earlier figure.
This study has several limitations. The diagnoses of
COPD, AsP, and CAP were based on physician-based
assessments. The accuracy of the diagnosis was not certified
by specialists. However, in normal clinical settings, these
diseases are not always diagnosed by specialists, and so we
believe the data relating to physician-based diagnosis to be
meaningful. In addition, cases of pneumonia not having
been diagnosed on admission but being diagnosed within
the first 48 hours after admission may have been excluded
in this study: such cases may not have appeared in the
category of hospital-acquired pneumonia. Thus, AsP
and CAP may have been underestimated in the present
study. Further, the degree of airflow limitation was not
evaluated in this study: the database does not include
the stages of COPD severity or details of pulmonary
function tests, including forced expiratory volume in
1 second and other indices. Thus, we cannot evaluate the
association between mortality and degree of lung function.
Conclusion
In conclusion, this study demonstrates that AsP has differ-
ent characteristics to CAP and that AsP is associated with
higher in-hospital mortality than CAP in COPD patients.
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